

# INTERNATIONAL SEARCH REPORT

International Application No  
/GB2004/050025

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/495 A61K31/704 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/69441 A (LOPEZ LAZARO LUIS ; JIMENO JOSE (ES); PHARMA MAR SA (ES); GUZMAN CECIL) 23 November 2000 (2000-11-23) cited in the application	1,3-5, 14-18
Y	page 8, lines 9-13,25 page 13, lines 13-17; claims 1,16,9,10	2,6-13
X	WO 03/039571 A1 (PHARMAMAR S.A; JIMENO, JOSE; RUIZ CASADO, ANA; LOPEZ LAZARO, LUIS; ROW) 15 May 2003 (2003-05-15)	1,3, 14-18
Y	page 11, paragraph 2; claims 1,3,6,13-15,17	2,6-13
X	WO 02/36135 A (PHARMA MAR SA ; GESCHER ANDREAS (GB); GIAVAZZI RAFAELLA (IT); INCALCI) 10 May 2002 (2002-05-10)	18
Y	cited in the application claims 1,4,6; example 7	1-17
	----- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

27 January 2005

Date of mailing of the international search report

14/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Allnutt, S

# INTERNATIONAL SEARCH REPORT

International Application No  
'6B2004/050025

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>TAKAHASHI N ET AL: "Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells."</p> <p>CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. OCT 2001, vol. 7, no. 10, October 2001 (2001-10), pages 3251-3257, XP002314514 .</p> <p>ISSN: 1078-0432</p> <p>page 3251, paragraph 3-12</p> <p>page 3256, column 1, lines 26-28</p>	1-18
Y	<p>VAN KESTEREN CH ET AL: "Yondelis(R) (trabectedin, ET-743): The development of an anticancer agent of marine origin."</p> <p>ANTI-CANCER DRUGS, vol. 14, no. 7, August 2003 (2003-08), pages 487-502, XP009042983</p> <p>ISSN: 0959-4973</p> <p>page 494, column 2, paragraph 4</p> <p>page 495, column 1, lines 10,11, paragraph 4</p> <p>page 497, column 1, paragraph 1</p> <p>page 500, column 1, paragraph 3</p>	1-18
Y	<p>VAN KESTEREN CHARLOTTE ET AL: "Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study"</p> <p>ANTI-CANCER DRUGS, vol. 13, no. 4, April 2002 (2002-04), pages 381-393, XP009042982</p> <p>ISSN: 0959-4973</p> <p>page 381, column 1, lines 4-6</p> <p>page 383, lines 23-27</p> <p>page 388, column 2, lines 9-16</p> <p>page 392, column 1, paragraph 2</p>	1-18
Y	<p>LAVERDIERE CAROLINE ET AL: "Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma."</p> <p>CANCER, vol. 98, no. 4, 15 August 2003 (2003-08-15), pages 832-840, XP002314512</p> <p>ISSN: 0008-543X</p> <p>page 833, column 2, lines 40-3</p> <p>page 835, column 2, lines 29-32</p> <p>page 838, column 1, lines 5-8</p>	1-18
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No

/GB2004/050025

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>GIANNI L;GRASSELLI G, DE BRAUD F ETAL:            "Definition of the least toxic sequence            and optimal therapeutic dose of Yondelis            in combination with doxorubicin in            patients with untreated metastatic soft            tissue sarcomas"            CLINICAL CANCER RESEARCH,            vol. 9, no. 16,            1 December 2003 (2003-12-01), page 6081S,            XP001205017            the whole document</p> <p>-----</p>	<p>1, 3-8,            14-18</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/050025

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-15  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
/GB2004/050025

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0069441	A	23-11-2000	AU 777417 B2	14-10-2004
			AU 4597500 A	05-12-2000
			BG 106171 A	28-06-2002
			BR 0010531 A	04-06-2002
			CA 2373794 A1	23-11-2000
			CN 1360503 T	24-07-2002
			CZ 20014081 A3	13-11-2002
			EP 1176964 A1	06-02-2002
			WO 0069441 A1	23-11-2000
			HU 0201187 A2	28-09-2002
			JP 2002544231 T	24-12-2002
			MX PA01011562 A	30-07-2002
			NO 20015516 A	11-01-2002
			NZ 515423 A	30-04-2004
			PL 352931 A1	22-09-2003
			SK 16442001 A3	05-03-2002
			TR 200103819 T2	22-04-2002
			NZ 529801 A	19-12-2003
WO 03039571	A1	15-05-2003	BR 0213424 A	14-12-2004
			CA 2462502 A1	15-05-2003
			EP 1435988 A1	14-07-2004
			US 2005004018 A1	06-01-2005
WO 0236135	A	10-05-2002	AU 1249902 A	15-05-2002
			BG 107843 A	30-06-2004
			BR 0115162 A	21-10-2003
			CA 2428160 A1	10-05-2002
			CN 1486193 T	31-03-2004
			CZ 20031327 A3	12-11-2003
			EP 1365808 A2	03-12-2003
			WO 0236135 A2	10-05-2002
			HU 0400648 A2	28-06-2004
			JP 2004517056 T	10-06-2004
			NO 20032027 A	04-07-2003
			NZ 525730 A	24-12-2004
			PL 361389 A1	04-10-2004
			SK 5492003 A3	02-03-2004
			US 2004108086 A1	10-06-2004